98%
921
2 minutes
20
The dataset presented here is related to a previous research article titled "Mitochondrial Complex III in Larval Stage of as a Potential Chemotherapeutic Target and in vivo Efficacy of Atovaquone Against Primary Hydatid Cysts"[1]. In this report, data were collected from aerobic and anaerobic culture assays of protoscoleces in the presence of three anti-echinococcal drug candidates (atovaquone, mefloquine, and 3-bromopyruvic acid). The data were analyzed for viability of the protoscoleces between day 0 and day 7 upon adding drug candidates. In aerobic condition, all drug candidates caused damage to the protoscoleces, as described previously [1], [2], [3], [4], [5], [6]. Mefloquine, alone as well as in combination with atovaquone, immediately eliminated the protoscoleces, whereas combination of atovaquone with 3-bromopyruvic acid did not show clear synergy. In anaerobic condition, mefloquine, alone as well as in combination with atovaquone, eliminated protoscoleces immediately. 3-Bromopyruvic acid showed stronger efficacy in anaerobic condition than in aerobic condition. Combination of atovaquone with 3-bromopyruvic acid eliminated the protoscoleces, indicating that synergy occurred only under anaerobic condition. The data clarified that combined use of the three drugs eliminated protoscoleces in both aerobic and anaerobic conditions, hence suggesting that these could inhibit aerobic and anaerobic respiration pathways of in vivo. The obtained data would be useful for the development of new drug dosing method for alveolar echinococcosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679680 | PMC |
http://dx.doi.org/10.1016/j.dib.2022.108707 | DOI Listing |
Pathogens
June 2025
Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro 21590-902, RJ, Brazil.
is a kinetoplastid parasite and etiological agent of Chagas disease. Given the significant morbidity and mortality rates of this parasitic disease, possible treatment alternatives need to be studied. 3-Bromopyruvate (3-BrPA) is a synthetic analog of pyruvate that was introduced in the early 21st century as an anticancer agent, affecting the proliferation and motility of certain microorganisms.
View Article and Find Full Text PDFMed Oncol
July 2025
Department of Physiology, Gülhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Colon cancer is particularly increasing in incidence in developed countries, and it ranks first in terms of morbidity and mortality worldwide. As in other types of cancer, metabolic changes and cellular death mechanisms play a critical role in cancer treatment. Cancer cells prefer glycolysis for energy production even in the presence of oxygen; this phenomenon is known as the Warburg effect.
View Article and Find Full Text PDFRSC Adv
June 2025
School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University Kunming City 650500 China
A Pt(iv) prodrug of oxaliplatin incorporating the glycolysis inhibitor 3-bromopyruvic acid, BrPt3, was designed and investigated. The prodrug is reduced in the presence of ascorbic acid, releasing its active Pt(ii) species and axial ligand. In cytotoxicity studies, BrPt3 exhibited stronger anticancer activity than oxaliplatin against all tested cancer cell lines, particularly in oxaliplatin-resistant A549/OXP cells.
View Article and Find Full Text PDFCancers (Basel)
June 2025
Institute of Oncology Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Background/objectives: Reprogramming of the cellular metabolism is a hallmark of cancer, offering therapeutic opportunities to target cancer cell vulnerabilities for therapeutic purposes. 3-Bromopyruvate (3BP) is a small alkylating agent that functions as an anti-metabolite, targeting key substrates in cancer metabolism and demonstrating antitumor activity across multiple cancer types. However, unformulated 3BP is associated with significant toxicity.
View Article and Find Full Text PDFElife
May 2025
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, United States.
Nearly 30% of pancreatic ductal adenocarcinomas (PDACs) exhibit a marked overexpression of monocarboxylate transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in clinical trials. In this study, we present an alternative approach using 3-bromopyruvate (3BP) to target MCT1 overexpressing PDACs.
View Article and Find Full Text PDF